John Mulligan, Bonum Therapeutics CEO
The crew that sold its lead IL-2 program to Roche is back with $93M to work on more next-gen I/O drugs
John Mulligan was in the process of raising about $90 million for a Series B to take Good Therapeutics’ PD-1-regulated IL-2 into the clinic when …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
